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Introduction
Testicular germ cell tumor (TGCT) is the most prevalent carcinoma in young men, and its incidence has been increasing over the past several decades in most population (1) . Prior to 1970, 95% of men with metastatic TGCTs died of their disease (2) . But the breakthrough in the treatment of metastatic TGCTs was achieved in the mid-1970s by the diaminodichloroplatinum (cisplatin) (2, 3) . Although TGCT is considered a paradigm of cisplatin-sensitive solid tumors (4), about 15-20% of patients with metastatic TGCT patients will relapse after cisplatin-based therapy (5) . Treatment options for cisplatin-resistant patient are scarce and identification of new therapeutic target is urgent.
Most malignant tumors of the testis are germ cell tumors (6) . Teratocarcinomas are a specific type of germ cell tumors that are composed of undifferentiated stem cells and differentiated clones that constitute endodermal, mesodermal and ectodermal germ layers (7) . Undifferentiated carcinoma cells can be
Materials and methods

Reagents
The Spectrum Collection TM chemical library was purchased from MicroSource Discovery Systems, Inc. (CT). All chemicals used in the study including, DMSO (dimethyl sulfoxide), KRIBB53 (97% purity, SigmaAldrich catalog # 534137), KRIBB57 (3,4-dimethoxychalcone; Sigma catalog # S798126), MG-132, PD98059, U0126, Z-VAD-fmk, EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride), DMF (N,Ndimethylformamide), chloroquine and DMA (N,N-dimethylacetamide) were purchased from Sigma (St Louis, MO). Cremophor EL was purchased from Calbiochem (Darmstadt, Germany). DMAP (4-Dimethylaminopyridine) was purchased from TCI (Tokyo, Japan). M-PER (78501) were purchased from Thermo Fisher Scientific (Waltham, MA). Protease inhibitor cocktail (11 873 580 001) and Pronase (10165921001) were purchased from Roche Applied Science (Indianapolis, IN). Antibodies against OCT4 (#2750), SOX2 (#3579), NANOG (#4903), PARP (#9542), phospho-ERK (#9101), ERK (#9102), phosphor-AKT(S473) (#9271), phosphor-AKT(T308) (#4056), survivin (#2803), Bim (#2933), Bcl-2 (#2872), Bax (#2772), Caspase3 (#9662) and STAT3 (#9139) were purchased from Cell Signaling Technology (MA), and antibodies against USP44 (sc-79329), c-MYC (sc-40), OCT3/4A/B (sc-5279), Actin (sc-47778), GAPDH (sc-47724) and Mcl-1 (sc-819) were purchased from Santa Cruz Biotechnology (TX). Antibody against HIF1 was purchased from BD Bioscience Pharmagen (San Jose, CA). The horseradish peroxidaseconjugated goat antirabbit, mouse antirat and goat antimouse IgG were obtained from Jackson ImmunoResearch (West Grove, PA).
Cell culture
NCCIT (CRL-2073), HFF-1 (CRL-1634), MCF10A (CRL-10317) and HCT116 (CCL-247) cell lines were obtained from ATCC (Manassas, VA). Tera-1 (HTB-105) cell line was obtained from Korean Cell Line Bank (KCLB, Seoul). NCCIT, Tera-1, HCT-116 and MCF10A cells were maintained in RPMI 1640 (Invitrogen). All culture media were supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen). The ampule passage number of NCCIT from ATCC was written as unknown. We used NCCIT cells up to 10 passages. Other cell lines were used for about 20 passages. Cell cultures were maintained at 37°C in 5% CO 2 in an incubator. The Cell lines were authenticated by the KCLB and showed >90% similarity in short tandem repeats (STR) profile when compared with the ATCC and KCLB databases.
Luciferase reporter construct and dual-luciferase reporter assay p(ORE)-TA-Luc plasmid was constructed by inserting the OCT4 response element (ORE) (5′-AAGTTA AAATCACATTTGAAATGCAAATGGAAAAGC-3′) in front of the pTA-Luc promoter vector (Clontech, CA). Oligonucleotide sequence are from the first intron of osteopontin gene that binds to OCT4 (24) . Nucleotide sequence in bold is OCT4 binding motif. The activity of the reporter was measured using a Dual-Luciferase reporter system (Promega, Madison, WI). NCCIT or Tera-1 cancer cells were seeded at a density of 2 × 10 6 cells in 100 mm 2 culture dishes. Cells were co-transfected with 4.5 μg p(ORE)-TA-Luc vector and 0.5 μg pRL-TK containing the Renilla luciferase gene as an internal control vector. The transfection was performed using TransFectin (Bio-Rad) according to the manufacturer's protocol. Five hours after transfection, cells were trypsinized and seeded onto sterilized, blackbottom, 96-well plates at a density of 2 × 10 4 cells per well. After incubation for 12 h, cells were treated with chemicals at 10 µM and then incubated further at 37°C for 48 h. Firefly and Renilla luciferase activities were measured using a dual-light reporter gene assay kit (Promega) with a GloMax TM 96 Microplate Luminometer (Promega). We initially chose hit compounds that inhibited pORE-TA-Luc reporter activity more than 70% compared with dimethyl sulfoxide (DMSO). Relative luciferase activity was calculated as according to the formula: relative luciferase activity (%) = [(normalized luciferase activity of sample treated with a test compound)/(normalized luciferase activity of sample treated with 0.1% DMSO) × 100.
Cell proliferation assay
Proliferation assay was performed as described previously (25) . Cells were seeded onto 96-well plates at a density of 5 × 10 3 cells per well in RPMI 1640 medium with 10% fetal bovine serum. After 18 h, the medium was replenished with fresh complete medium containing chemicals or 0.1% DMSO. After incubation for 48 or 72 h, the cell proliferation reagent WST-1 (Dojindo, Japan) was added to each well. The amount of WST-1 formazan produced was measured at 450 nm using an ELISA reader (BioRad). In some case, as indicated, the number of cells were counted using microscope.
Knockdown of proteins using siRNA
Knockdown of protein was performed as described previously (26) . Two different human OCT4 small interfering RNAs were synthesized as duplexes (Bioneer, Korea): (siOCT4-1), 5′-AAGGAUGAGGUCCGAGUGUGG-3′ and (siOCT4-2), 5′-GAAAGAACUCGAGCAAUUU-3′. A negative control siRNA, 5′-CCUACGCCACCAAUUUCGU-3′, was purchased from Bioneer, Inc. (Daejeon, Korea). Five hours after transfection, the medium was replaced with fresh medium containing 10% fetal bovine serum and further incubated for 72 h. Quantitation of mRNA using quantitative real-time reverse transcription PCR Quantitation of mRNA was performed as described previously (26) . The following primers were used for RT-PCR: OCT4 forward primer,  5′-CTTCTCGCCCCCTCCAGGTC-3′; OCT4 reverse primer, 5′-AAATAGAAC  CCCCAGGGTGAGC-3′; NANOG forward primer, 5′-CAGAAGGCCTCA  GCACCTAC-3′; NANOG reverse primer, 5′-ATTGTTCCAGGTCTGGTTGC-3′; USP44 forward primer, 5′-CTCACAGAAGCCCAGAAACA-3′; USP44 reverse primer, 5′-AAAGCCAACATGAACACCAA-3′; GAPDH forward primer, 5′-GGGAGCCAAAAGGGTCATCATCTC-3′ and GAPDH reverse primer, 5′-CCATGCCAGTGAGCTTCCCGTTC-3′. Relative quantities of OCT4 mRNA were normalized against GAPDH mRNA.
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Western blotting
Lysates were prepared using RIPA buffer as described previously (25) . Total protein concentrations were measured with Bradford protein assay. A volume of lysate corresponding to 10 or 20 μg was subjected to SDS-PAGE and transferred to a PVDF membrane (Millipore). High-detergent lysis buffer contained 4% SDS, 4% 2-mercapto-ethanol, 20 mM Tris-HCl pH 6.8, 30% glycerol and 0.2% bromophenol blue. Proteins were detected with the indicated primary antibodies. The secondary antibodies used were horseradish peroxidase-conjugated goat antirabbit, mouse antirat and goat antimouse IgG (Jackson Immunoresearch Laboratories, Inc.) The blots were developed with an enhanced chemiluminescence detection reagent (Roche, Germany). Blots were imaged using the ImageQuant LAS 4000, and protein band intensities were analyzed using the MultiGauge version 3.0 software provided with the ImageQuant LAS 4000.
FACS analysis
NCCIT cells were treated with KRIBB53 at 10 and 20 μM for 24 h. Cells were then harvested by trypsinization, fixed with 70% chilled ethanol and preserved at −20°C before FACS analysis. Fixed cells were washed twice with phosphate-buffered saline (PBS) solution before being suspended in 500 μl PBS and treated with 100 mg/ml RNase A at 37°C for 30 min. Propidium iodide was then added to a final concentration of 50 mg/ml for DNA staining, and 20 000 fixed cells were analyzed on a FACScalibur system (BD Biosciences). Cell cycle distribution was analyzed using the Modifit program (BD Biosciences).
Synthesis of biotinyl-KRIBB53
Sixty-five milligrams (0.18 mM) of N-biotinylcaproic acid, 34 mg of EDC and 3 mg of DMAP were added in DMF, to which 50 mg (0.15 mM) of KRIBB53 was added. The reaction mixture was stirred for 2 h at 50°C under N 2 to ensure completely dissolution and was then stirred overnight under N 2 at room temperature. The reaction solution was dried in vacuo and purified by HPLC yielding 23 mg of biotinyl-KRIBB53 (Supplementary Figure 8 , available at Carcinogenesis Online). We confirmed biotinyl-KRIBB53 structure by 1H-NMR, 13C-NMR and 2-D NMR (including HMQC, COSY and HMBC).
Affinity chromatography with biotinyl-KRIBB53
Affinity chromatograpy was performed as described previously with some modifications (26) . NCCIT cells were washed with cold PBS and then lysed with homogenization buffer [60 mM β-glycerophosphate, 25 mM MOPS (pH 7.2), 15 mM EGTA, 1 mM DTT, 1 mM phenyl phosphate, 100 µM benzamidine]. Cell lysates was centrifuged at 13 000 rpm for 15 min at 4°C, and the supernatant was collected. The cell lysates (70 µg) were incubated with biotinyl-KRIBB53 for 2 h at 4°C in the absence or presence of KRIBB53. Proteins associated with the biotinyl-KRIBB53 compound were precipitated with NeutrAvidin-agarose resin and washed six times with 500 µl bead buffer [50 mM Tris (pH 7.4), 5 mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40, 10 µg/ml of leupeptin, aprotinin and soybean trypsin inhibitor and 100 µM benzamidine]. Samples were boiled in SDS-PAGE sample buffer, separated by 12.5% polyacrylamide gel electrophoresis and immunoblotted with an antibody against OCT4.
DARTS assay
Drug affinity responsive target stability (DARTS) assays were performed as described previously with some modifications (27, 28) . NCCIT cells were cultured to 70-80% confluency in 100 mm 2 culture plates. After washing one time with ice-cold PBS, the cells were treated with ice-cold M-PER lysis buffer [M-PER (Thermo Fisher Scientific, Rockford, IL) supplemented with 1× protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN), 1 mM Na 3 VO 4 (Sigma-Aldrich, St. Louis, MO) and 1 mM NaF (SigmaAldrich)]. After collecting the cells with a scraper, the cells were incubated for 10 min at 4°C. Cell lysates were centrifuged at 13 000 rpm for 10 min, and the supernatant was diluted with M-PER lysis buffer to a final protein concentration of 2 mg/ml. The protein lysates (600 μl) were mixed with 66.7 μl of 10× TNC buffer (500 mM Tris-HCl, pH 8.0, 500 mM NaCl and 100 mM CaCl 2 ) (Sigma-Aldrich). The lysates were split into two 1.5 ml tubes (297 μl) and incubated with 3 μl of either DMSO or KRIBB53 (30 mM) for 1 h at room temperature. Following the incubation, each sample was split into six aliquots of 50 μl each (50 μg in proteins) and proteolyzed in various concentrations of Pronase (25, 50, 125, 250 and 500 ng) (Roche Applied Science) for 10 min at room temperature. After 10 min, 2 μl of ice-cold 20× protease inhibitor cocktail was added to stop proteolysis and immediately placed on ice. Digestion was further stopped by adding 5× sample loading dye and boiling at 95°C for 10 min. Equal portions of each sample were then loaded onto SDS-PAGE gels for western blotting.
Nude mouse xenograft assay
All animals were housed in a pathogen-free animal facility at the Korea Research Institute of Bioscience and Biotechnology (KRIBB). Six-weekold littermate mice were used in all experiments according to protocols approved by the policy of the KRIBB Animal care and use committee. NOD. CB17-Prkdc scid Il2rg tm1Wjl /SzJ mice, purchased from the Jackson Laboratory, were used for implantable tumor studies. Six-week-old NOD.CB17-Prkdc scid Il2rg tm1Wjl /SzJ mice were used for NCCIT xenografts. Flanks of each mouse were injected with 5 × 10 6 cells mixed with Matrigel Matrix (BD Biosciences) in a total volume of 100 μl. KRIBB53 was dissolved in 10% DMA (N,N-dimethylacetamide), 10% Cremophore and 80% distilled water. One day after tumor challenge, control solution (100 μl) or KRIBB53 (30 mg/kg) was intraperitoneally injected daily for 50 days. Because of the ease of administration than other methods, we used intraperitoneal injection. Tumor measurements were performed every 3 days with a caliper, and volumes were calculated using the formula:
Statistical analysis
The data are expressed as the means ± standard deviations (SDs), and the degree of significance was analyzed using Student's t-test. P values below 0.05 were considered to indicate statistical significance. *P < 0.05 versus control and **P < 0.01 versus control. All the tested concentrations were compared against the vehicle control to get the P value using Student's t-test. The half maximal inhibitory concentration (IC 50 ) value was determined from the plot made using SigmaPlot software with curved model of Logistic, 4 parameter.
Results
OCT4-targeted screening identifies KRIBB53 as an inhibitor of OCT4 activity
We determined whether proliferation of NCCIT cells was decreased by OCT4 siRNA treatment. As shown in Figure 1A , depletion of OCT4 significantly decreased the number of NCCIT cells, showing up to 70% inhibition compared with control siRNA, suggesting OCT4 as a potential therapeutic target for TGCT.
To screen OCT4 inhibitors from a chemical library, an OCT4-dependent luciferase reporter plasmid, pORE-TA-Luc, was constructed by introducing an ORE (OCT4 response element) into the pTA-Luc vector. To confirm that pORE-TA-Luc could be used to identify inhibitors of OCT4, the effects of OCT4 expression on reporter activity were tested by cotransfecting HCT-116 cells with a pORE-TA-Luc reporter and the pCDNA3-OCT4 plasmid at different concentrations. To normalize for transfection efficiency, an internal control vector constitutively expressing pRL-TK was co-transfected. After 48 h, luciferase activity was measured. In response to exogenous OCT4 expression, a 40-fold increase in luciferase activity was observed in HCT-116 cells ( Figure 1B) .
Following the validation of the pORE-TA-Luc reporter in the cell-based assay, a structurally diverse chemical library of 2000 compounds (The Spectrum Collection TM chemical library from MicroSource Discovery Systems, Inc.) was screened. This chemical library is composed of marketed and experimental drugs and natural products. To screen inhibitors of OCT4 activity, human embryonal carcinoma NCCIT cells that endogenously express OCT4 were used. From this screen, we identified three hit compounds (methyl robustone, resveratrol and 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone) that inhibited pORE-TA-Luc reporter activity more than 70% compared with DMSO. The Renilla luciferase activity of cells treated with methyl robustone, resveratrol and 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone are, 2268 (arbitrary unit), 1950 and 995, respectively. Next, we tested whether these hits were false positive by inhibiting firefly luciferase itself. For this, NCCIT cells expressing pORE-TALuc reporter were lysed first and then the lysates were treated with the hit compounds at 10 μM for 20 min at 4°C. And then immediately, luciferases activity was measured. Both methyl robustone and resveratrol inhibited luciferase activity of lysates by 97% compared with DMSO, indicating robustone and resveratrol are false positive. In contrast, 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone did not inhibit luciferase of cell lysates, indicating 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone is not false positive and therefore, we decided to characterize 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone further. For this, we purchased 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone from Sigma-Aldrich (catalog # 534137) and have used this in this study. During the reviewing process of our results, reviewer suggested to provide structural information of the biotinylated 2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone. We took NMR analysis of both the hit compound that we bought from Sigma-Aldrich and the biotinylated hit compound that we synthesized. Surprisingly, we found that correct structure (2′,4-dihydroxy-3,4′,6′-trimethoxychalcone) of the compound bought from Sigma-Aldrich was different from the structure (2′,4-dihydroxy-3′,4′,6′-trimethoxychalcone) shown in Sigma-Aldrich catalog. We identified the active compound structure by 1 H-NMR, 13 C-NMR, and 2-D NMR (including HMQC, COSY and HMBC). Therefore, in order to prevent any misunderstanding of the structure of active compound used in this study, we called 2′,4-dihydroxy-3,4′,6′-trimethoxychalcone as 'KRIBB53' ( Figure 1D ). KRIBB57 (3,4-dimethoxychalcone) is a structural analogue of KRIBB53 and could not inhibit OCT4-dependent luciferase activity ( Figure 1C and D) , suggesting that the specific structure of KRIBB53 is important for its OCT4 inhibitory activity.
Inhibition of the expression of the OCT4 target genes NANOG and USP44 by KRIBB53
Next, we wanted to confirm the inhibitory activity of KRIBB53 on OCT4 in a different human EC cell line. For this, the OCT4 reporter plasmid was transfected into NCCIT or Tera-1 cells and incubated for 24 h. Twelve hours after OCT4 reporter introduction, cells were treated with KRIBB53 for 48 h. As shown in Figure 2A and B, KRIBB53 inhibited OCT4-dependent luciferase activity in a dose-dependent manner, with IC 50 of 3 or 4 μM in NCCIT and Tera-1 cells, respectively. Because doubling times are 1 and 3 days for NCCIT and Tera-1 cells, respectively, we mainly used NCCIT cells for further study. was normalized against the GAPDH gene. Each experiment was repeated three times, and each value is the mean ± SD. Statistical significance (P value) was determined with an unpaired t test. *P < 0.05; **P < 0.01 versus control.
Because KRIBB53 decreased OCT4 reporter activity, effect of KRIBB53 on the OCT4 downstream genes was investigated. For this, NCCIT cancer cells were exposed to KRIBB53 at different concentrations for 12 h. Treating NCCIT cancer cells with KRIBB53 blocked OCT4-dependent NANOG and USP44 mRNA expression levels in a concentration-dependent manner, with IC 50 of 13 and 15 μM, respectively ( Figure 2C and D) . In accordance with its effect on mRNA expression, KRIBB53 also significantly down-regulated the OCT4 target proteins NANOG and USP44 in a concentration-dependent manner ( Figure 2E) . Collectively, these results demonstrated that KRIBB53 is an effective inhibitor of OCT4 activity.
To analyze the temporal changes in NANOG and USP44 expression caused by KRIBB53, NCCIT cells were treated with 20 µM KRIBB53 for different time periods. As shown in Figure 2F and G, treating NCCIT cancer cells with KRIBB53 decreased the expression of NANOG and USP44 mRNA 3 h after treatment. In accordance with its effect on mRNA expression, KRIBB53 also significantly down-regulated the OCT4 target protein NANOG in a time-dependent manner ( Figure 2H ). Next we tested whether KRIBB53 could induce lineage-specific marker expression. For this, we analyzed the expression of BMP4, a mesoderm marker (19) . Treating NCCIT cells with KRIBB53 increased the expression of BMP4 mRNA up to 2.5-fold ( Figure 2I ). This BMP4 induction by KRIBB53 is consistent with a previous report that OCT4 knockdown using siRNA induced BMP4 expression in NCCIT cells (19) .
KRIBB53 decreased OCT4 protein levels
To assess effect of KRIBB53 on OCT4 transcription, NCCIT cancer cells were exposed to KRIBB53 (0-30 µM) for 12 h and OCT4 mRNA expression was analyzed by quantitative RT-PCR. As shown in Figure 3A , KRIBB53 did not inhibit the transcription of the OCT4 gene when treated with doses up to 20 µM. Similarly, KRIBB53 did not inhibit the transcription of the OCT4 gene up to 12 h after KRIBB53 treatment ( Figure 3B ). These results suggest that KRIBB53 decrease levels of OCT4 protein by inhibiting posttranscriptional stages of OCT expression. Because treating cells with KRIBB53 at 20 µM for 24 h induced significant apoptotic cell death ( Figure 5E ), quantitative evaluation of mRNA may not be adequate at 24 h.
To characterize the mechanism of KRIBB53 action on OCT4 inhibition, we analyzed OCT4 expression in NCCIT cells after treating cells with KRIBB53 at 20 µM for 12 h. Unexpectedly, KRIBB53 significantly decreased levels of OCT4 proteins in a concentration-and time-dependent manner ( Figure 3C and D) . It is possible that KRIBB53 inhibited translation of OCT4 protein.
Even though it is less likely, we considered the possibility that OCT4 was poorly solubilized by RIPA buffer when treated with KRIBB53. Recently, the STAT3 inhibitor OPB-51602 has been shown to lead to the accumulation of STAT3 aggregates that were not solubilized by RIPA buffer (29) . Therefore, we used highdetergent lysis buffer for OCT4 detection. Similar to lysis by RIPA buffer, lysis of NCCIT cells in high-detergent lysis buffer did not abolish KRIBB53-induced OCT4 downregulation (Supplementary Figure 7 , available at Carcinogenesis Online). This result indicated that KRIBB53 did not decrease levels of OCT4 through OCT4 aggregation.
KRIBB53 decreases levels of OCT4 by inducing its degradation
Because KRIBB53 did not inhibit OCT4 transcription ( Figure 3A and B) but did decrease the levels of the OCT4 protein ( Figure 3C and D), we tested possibility that KRIBB53 inhibited translation of OCT4 mRNA. We used a co-treatment strategy. If KRIBB53 is a translation inhibitor like cycloheximide (CHX), and the cells are treated with high enough concentrations of CHX to block translation, co-treatment of KRIBB53 should not show additive effects. Treating NCCIT cells with either KRIBB53 or CHX decreased levels of OCT4, and co-treatment of KRIBB53 with CHX further decreased levels of OCT4 protein compared to treatment of either alone ( Figure 3E ). These results suggested that KRIBB53 is not a translation inhibitor but rather an enhancer of OCT4 degradation. This additive degradation was detected only for OCT4 and was not detected with NANOG. In addition, KRIBB53 could not decrease c-MYC protein levels ( Figure 3E ). These results strongly suggested that KRIBB53 is an OCT4-specific inhibitor.
Next, we tested whether KRIBB53 enhanced OCT4 downregulation through proteasome-dependent degradation. We used MG132 as an inhibitor of the proteasome. When NCCIT cells were treated with CHX, level of OCT4 protein was significantly decreased ( Figure 3F lane 2 versus lane 1) , and pretreating cells with MG132 for 2 h remarkably rescued CHX-induced OCT4 downregulation ( Figure 3F lane 3 versus lane 2) . These results are consistent with a previous report that OCT4 is normally degraded by the proteasome (30) . Similarly, when NCCIT cells were treated with KRIBB53, the level of OCT4 protein was significantly decreased ( Figure 3F Lin and colleagues reported that AKT phosphorylated OCT4 at threonine 235, increasing its stability (30) . Therefore, we tested whether the activity of AKT was inhibited by KRIBB53 using an active-specific antibody. NCCIT cells were treated with KRIBB53 at different concentrations or for different times. As shown in Figure 3G and H, the activity of AKT was not inhibited by KRIBB53, suggesting that KRIBB53 decreased the OCT4 protein levels in an AKT-independent manner.
KRIBB53 enhances OCT4 degradation through direct association
Target identification is a major challenge for a phenotype-based approach. To identify target proteins, biotinyl-KRIBB53 was synthesized as described in the Materials and Methods. The synthesized biotinyl-KRIBB53 had comparable inhibitory activity to KRIBB53 (IC 50 of 20 versus 14 μM, respectively) (Supplementary Figure 9 , available at Carcinogenesis Online). Because of the low sensitivity of Coomassie Brilliant Blue staining, we used an antibody that is highly sensitive and specific. As KRIBB53 enhanced the degradation of the OCT4 protein, we evaluated whether biotinyl-KRIBB53 directly associates with the OCT4 protein. Cell extracts of NCCIT were incubated with biotinyl-KRIBB53. The bound proteins were precipitated with NeutrAvidin-agarose resin, resolved using SDS-PAGE and immunoblotted with OCT4 antibody ( Figure 4A ). When the interaction between OCT4 and biotinyl-KRIBB53 was challenged by excess KRIBB53, the interaction between OCT4 and biotinyl-KRIBB53 was decreased, suggesting specific interaction of KRIBB53 with OCT4 ( Figure 4A) .
We wanted to confirm the association of KRIBB53 with OCT4 using another method. The DARTS assay is based on the assumption that binding of a drug generally stabilizes a target protein (27) . However, depending on the drug-target identity, drug binding might also increase the proteolytic susceptibility and whole cell lysates were analyzed by western blot. Each experiment was repeated two times, and each value is the mean ± SD. Statistical significance (P value) was determined with an unpaired t test. **P < 0.01 versus control. (E) NCCIT cells were treated for 6 h with 20 μM of KRIBB53, 20 μg/ml of CHX, or both and then the whole cell lysates were analyzed by western blot. (F) NCCIT cells were pretreated with 5 μM MG132, 100 μM CQ, or vehicle solvent (0.1% DMSO) for 2 h and then exposed to of the target protein (27, 31) or destabilize protein folding (32) . Interestingly, treating cell lysates with only KRIBB53 for 1 h was sufficient to induce OCT4 degradation by 52% ( Figure 4B top lane 1 and lane 2). Because cell lysates, but not live cells, were used, it was unlikely that regulatory signaling in the cells was involved in the KRIBB53-induced OCT4 degradation. In addition, addition of exogenous protease Pronase with KRIBB53 in cell lysates increased OCT4 proteolysis by 75% compared with proteolysis in the absence of KRIBB53 ( Figure 4B top lane 3 and lane 4). To confirm that KRIBB53 enhanced specific proteolysis of the OCT4 transcription factor, we analyzed proteolysis of STAT3 in the absence or presence of KRIBB53. As shown in Figure 4B middle, susceptibility of STAT3 was not altered by the presence of KRIBB53. Similarly, the non-target protein GAPDH was not sensitized by KRIBB53 (Figure 4B bottom) . This result suggested that enhanced proteolysis by KRIBB53 is target-specific. We obtained similar results from two independent assays.
Reduction of OCT4 expression causes apoptosis of NCCIT and Tera-1 cells
As shown in Figure 1A , siRNA-mediated OCT4 knockdown significantly decreased proliferation of NCCIT cells. Therefore, we tested whether KRIBB53 inhibited the proliferation of NCCIT cells. NCCIT cells were treated with different concentrations of KRIBB53 and the number of live cells was counted 72 h after treatment. KRIBB53 decreased the number of NCCIT cells in a concentration-dependent manner, with a GI 50 of 10 μM, where GI 50 is the inhibitor concentration at which a 50% inhibition of cell growth is observed ( Figure 5A ). We repeated the proliferation assay with Tera-1 cells, which also express endogenous OCT4 ( Figure 5B ). Treating Tera-1 cells with 30 μM KRIBB53 decreased the cell number by 70% compared with the control. To use KRIBB53 as a lead compound for development of anticancer therapeutics, it should not inhibit proliferation of normal cells. KRIBB53 had no effect on the proliferation of normal diploid human fibroblast cells and human epithelial cells (HFF and MCF10A; Figure 5A and B), suggesting that KRIBB53 could be a viable lead compound. In addition, we analyzed temporal pattern of NCCIT cell growth in the presence of KRIBB53 at different concentrations ( Figure 5C ). Doubling time of NCCIT cells was prolonged when the cells were treated with KRIBB53 at 5 and 10 μM. In addition, when NCCIT cells were treated with KRIBB53 at higher than 20 μM, number of live cells were decreased.
Because KRIBB53 inhibited proliferation of NCCIT cells, the phase of the cell cycle affected by the compound was evaluated. NCCIT cells were treated with KRIBB53 at different concentrations for 24 h and subjected to FACS analysis. KRIBB53 caused an increase in the proportion of the sub-G 1 population in a concentration-dependent manner, indicating KRIBB53-induced apoptosis ( Figure 5D ). To analyze the temporal pattern of the induction of apoptosis by KRIBB53, NCCIT cells were treated with 20 μM of KRIBB53 for different times. As shown in Figure 5E , treating NCCIT cells with KRIBB53 for 12 h induced PARP cleavage, and apoptotic cell death was increased in accordance with exposure times. Because PARP cleavage began to appear 12 h after KRIBB53 treatment ( Figure 5E ), NCCIT cells were treated with different concentrations of KRIBB53 for 12 h and analyzed whether the treatment activated caspase 3. As shown in Figure 5F , the temporal pattern of caspase-3 activation is consistent with PARP cleavage. Previously, OCT4 was shown to regulate Noxa, Bim, Puma and Mcl-1 (33) . However, KRIBB53 did not alter the endogenous expression levels of Bcl-2, Mcl-1, Bcl-xL, Bax, BAK, Survivin and Bim, suggesting that the expression of these Bcl-2 family proteins is not involved in KRIBB53-induced apoptosis in the NCCIT cells ( Figure 5F ). To prove that KRIBB53 induces apoptosis of another OCT4-expressing cancer cells, we used Tera-1 cells for apoptosis assays. Tera-1 cells were treated with different concentrations of KRIBB53 for 12 h, and levels of OCT4 protein and PARP cleavage were evaluated ( Figure 5G and H). As expected, KRIBB53 decreased OCT4 expression and induced apoptosis of Tera-1 cells. /SzJ (NSG) mice were used to investigate the anti-tumor effects of KRIBB53 on tumor growth in vivo. Flanks of each mouse were injected with 5 × 10 6 cells mixed with Matrigel Matrix (BD Biosciences) in a total volume of 100 μl. One day after tumor challenge, control solution (100 μl) or KRIBB53 (30 mg/kg) was intraperitoneally injected daily for 50 days. To determine the toxicity of the compound, the body weights of tumor-bearing mice were measured. On day 51, the mice were sacrificed, and the tumors were removed and weighed. Mice treated with KRIBB53 showed a 77% (P < 0.001) decrease in tumor volume compared to control mice ( Figure 6A and C) . These results suggest that KRIBB53 could block the growth of tumors in an animal model. There was no change in body weights when KRIBB53 was used at 30 mg/kg ( Figure 6B ). To confirm that KRIBB53 suppressed the growth of NCCIT tumors through the induction of OCT4 degradation in vivo, OCT4 protein levels were measured in tumor tissues from both KRIBB53-and control-treated mice. As shown in Figure 6D , OCT4 protein levels were significantly decreased in tumors from mice treated with KRIBB53 compared with mice treated with vehicle. Although not statistically significant, the trend suggested that OCT4 loss could be due to KRIBB53 treatment ( Figure 6E ).
Discussion
Downregulation of OCT4 expression in NCCIT induces differentiation with mesodermal characteristics (19) and also leads to apoptosis (34) , suggesting OCT4 as a potential target for anticancer therapy. In this study, we identified KRIBB53 from a phenotype-based screening of an OCT4 inhibitor. We proved that KRIBB53 decreased expression of OCT4 target genes mRNA and proteins in a concentration-dependent and time-dependent manner ( Figure 2 ). Unexpectedly, KRIBB53 decreased the level of OCT4 protein but not mRNA. We considered two possibilities to explain this: either inhibition of OCT4 synthesis or enhancement of OCT4 degradation. By analyzing effects of KRIBB53 on the levels of OCT4 protein in the presence or absence of the general translation inhibitor CHX and the proteasomal inhibitor MG132 ( Figure 3E and F) , we proved that KRIBB53 enhanced OCT4 degradation in a proteasome-dependent manner.
Interestingly, the selective estrogen receptor down-regulators (SERDs) fulvestrant and GW5638 also bind to the estrogen receptor and induce rapid proteasomal-dependent degradation (35, 36) . Upon binding to the ER, fulvestrant induces a structural change that increases hydrophobicity of protein surface causing degradation. Currently, we do not know how KRIBB53 induced OCT4 degradation.
A formidable challenge during phenotype-based screening is the identification of the target protein of the active compound. Because KRIBB53 enhanced OCT4 degradation, we speculated that KRIBB53 might directly bind to OCT4. We tested this possibility by using biotinyl-KRIBB53 affinity chromatography ( Figure 4A ). We further confirmed KRIBB53 binding to OCT4 using DARTS assay. Without requiring chemical modification of the active compound, DARTS analysis allows the evaluation of direct binding of small compounds to a target protein (27) . Binding of a compound is expected to stabilize target protein or mask protease cleavage sites, thereby protecting them from protease digestion. However, in certain cases, compound binding increases proteolytic susceptibility of the target protein (31). When we incubated NCCIT cell lysates with KRIBB53 in vitro, the OCT4 protein was more susceptible to endogenous protease ( Figure 4B upper lanes 1 and 2) and to exogenous Pronase ( Figure 4B upper lanes 3 and 4, lanes 5 and 6) . Interestingly, the enhanced susceptibility to degradation of the OCT4 protein by KRIBB53 in the DARTS assay in vitro ( Figure 4B ) was consistent with down-regulation of the OCT4 protein when cells were treated with KRIBB53 ( Figure 3C and D) and when mice were administered KRIBB53 ( Figure 6D ).
How can inhibition of OCT4 induce apoptosis? Knockdown of OCT4 decreases pro-apoptotic Noxa expression, thus decreasing apoptosis (33) . In addition, silencing of OCT4 also reduced the BH3-only proapoptotic proteins Bim and Puma, suggesting antiapoptotic effects of OCT4 silencing. As shown in Figure 5E , treating NCCIT cells with KRIBB53 for 12 h induced PARP cleavage, and apoptotic cell death was increased in accordance with exposure times. The temporal pattern of caspase-3 activation was consistent with PARP cleavage ( Figure 5F ). However, when we treated NCCIT cells with KRIBB53, we could not detect any decrease in Mcl-1, Bcl-2, Survivin and Bcl-xL expression levels or any increase in Bim, Bax and Bak expression levels ( Figure 5F ). These results suggested that mechanisms of apoptosis by OCT4 inhibition is cell-type specific and currently we do not know how OCT4 downregulation by KRIBB53 induces apoptosis of NCCIT cells. This is the first report of an OCT4 inhibitor, KRIBB53, which directly binds to and induces OCT4 degradation via the proteasome. In addition, we demonstrated that KRIBB53 has anticancer activity using cancer cells and a mouse xenograft model. KRIBB53 can be used as a lead compound for the development of cancer therapeutics.
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